• No results found

University of Groningen Cost-effectiveness of vaccination strategies to protect older adults Boer ,de, Pieter Taeke

N/A
N/A
Protected

Academic year: 2021

Share "University of Groningen Cost-effectiveness of vaccination strategies to protect older adults Boer ,de, Pieter Taeke"

Copied!
9
0
0

Bezig met laden.... (Bekijk nu de volledige tekst)

Hele tekst

(1)

University of Groningen

Cost-effectiveness of vaccination strategies to protect older adults

Boer ,de, Pieter Taeke

DOI:

10.33612/diss.126806948

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version

Publisher's PDF, also known as Version of record

Publication date: 2020

Link to publication in University of Groningen/UMCG research database

Citation for published version (APA):

Boer ,de, P. T. (2020). Cost-effectiveness of vaccination strategies to protect older adults: Focus on herpes zoster and influenza. Rijksuniversiteit Groningen. https://doi.org/10.33612/diss.126806948

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

(2)

Cost-effectiveness of vaccination

strategies to protect older adults:

focus on herpes zoster and influenza

(3)

This thesis was financially supported by Sanofi Pasteur, AstraZeneca, and the World Health Organization

Financial support for the printing of this thesis was kindly provided by the University of Groningen, Research Institute SHARE, and the Graduate School of Science and Engineer-ing of the University of GronEngineer-ingen

ISBN: 978-94-034-2476-7 (printed version) ISBN: 978-94-034-2475-0 (electronic version)

Cover: Temps, Dietmar. Table Mountain with clouds, Cape Town, South Africa [Digital image]. Retrieved from www.shutterstock.com.

Print: Ridderprint | www.ridderprint.nl

© Pieter de Boer, 2020. No part of this thesis may be reproduced or transmitted in any form or by any means without written permission of the holder of the copyright

(4)

Cost-effectiveness of vaccination

strategies to protect older adults:

focus on herpes zoster and influenza

Proefschrift

ter verkrijging van de graad van doctor aan de Rijksuniversiteit Groningen

op gezag van de

rector magnificus prof. dr. C. Wijmenga en volgens besluit van het College voor Promoties.

De openbare verdediging zal plaatsvinden op vrijdag 19 juni 2020 om 11.00 uur

door

Pieter Taeke de Boer

geboren op 21 maart 1985

te Wonseradeel

(5)

Promotores

Prof. dr. M.J. Postma Prof. dr. J.C. Wilschut

Beoordelingscommissie

Prof. dr. J. Wallinga Prof. dr. P. Beutels Prof. dr. E. Buskens

(6)

Paranimfen

Werner Bijlsma Christiaan Dolk

(7)

Table of contents

Chapter 1 General introduction 9

Part I: Cost-effectiveness of vaccination against herpes zoster

Chapter 2 Cost-effectiveness of vaccination against herpes zoster 27 Chapter 3 Cost-effectiveness of vaccination of the elderly against herpes

zoster in The Netherlands

55 Chapter 4 Cost-effectiveness of vaccination of immunocompetent older

adults against herpes zoster in the Netherlands: a comparison between the adjuvanted subunit and live-attenuated vaccine

73

Chapter 5 The ‘dynamic’ marriage between varicella and zoster 103

Part II: Cost-effectiveness of vaccination against influenza

Chapter 6 A systematic review of the health economic consequences of quadrivalent influenza vaccination

109 Chapter 7 Cost-effectiveness of quadrivalent versus trivalent influenza

vaccine in the United States

141 Chapter 8 The cost-effectiveness of trivalent and quadrivalent influenza

vaccination in communities in South Africa, Vietnam and Australia

165

Annex to Chapter 8

Additional calculations belonging to the manuscript: The cost- effectiveness of trivalent and quadrivalent influenza vaccination in communities in South Africa, Vietnam and Australia

187

Chapter 9 Cost-effectiveness of paediatric influenza vaccination in The Netherlands

191 Chapter 10 Unremarked or unperformed? Systematic review on reporting

of validation efforts of health economic decision models in seasonal influenza and early breast cancer

217

(8)

Supplements Summary 262

Nederlandse samenvatting 266

List of publications 270

Dankwoord / Acknowledgements 272

Curriculum vitae 275

(9)

Referenties

GERELATEERDE DOCUMENTEN

In the Netherlands, for instance, only vaccination against influenza is currently offered free of charge to older adults, while in the UK, next to the flu shot, vaccination

When updated information on the duration of vaccine-induced protection, HZ incidence or vaccine price becomes avail- able, cost-effectiveness results should be updated in order

Our analysis shows that vaccination of Dutch elderly against HZ might be cost-effective for all vaccination ages ≥60 years, when a vaccine price of €93.45 including

Methods: Using a Markov model with a decision tree, we conducted a cost-effectiveness analysis of vaccination with HZ/su (two doses within 2 months) or zoster vaccine live (ZVL)

[3] analyzed the cost-effectiveness of varicella vaccination in the Netherlands using dynamic modelling with the Hope-Simpson hypothesis included and excluded.. Considering a

Then, the following in- formation was systematically extracted if possible/reported: (1) country of study, funding source, general characteristics of the analysis (type of

[10,11] estimated the mean incremental costs per influenza case averted at $1218, using the TPP perspective and an incremental vaccine price of $5.. Applying exactly the same

Cost-effectiveness acceptability curves of implementing influenza vaccination with trivalent in- fluenza vaccine and quadrivalent influenza vaccine in the communities Agincourt